Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 18(2022), 39 vom: 18. Dez., Seite 4235-4238 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cetin, Bulent [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abiraterone |
|---|
| Anmerkungen: |
Date Completed 23.03.2023 Date Revised 20.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2022-0668 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351621083 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351621083 | ||
| 003 | DE-627 | ||
| 005 | 20231226051828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2022-0668 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM351621083 | ||
| 035 | |a (NLM)36651304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cetin, Bulent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2023 | ||
| 500 | |a Date Revised 20.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a advanced prostate cancer | |
| 650 | 4 | |a homologous recombination repair | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a abiraterone |2 NLM | |
| 650 | 7 | |a G819A456D0 |2 NLM | |
| 650 | 7 | |a Androstenes |2 NLM | |
| 700 | 1 | |a Wabl, Chiara A |e verfasserin |4 aut | |
| 700 | 1 | |a Gumusay, Ozge |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 18(2022), 39 vom: 18. Dez., Seite 4235-4238 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:39 |g day:18 |g month:12 |g pages:4235-4238 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2022-0668 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 39 |b 18 |c 12 |h 4235-4238 | ||